Under the agreement, the two organizations will share information on their respective projects and exchange insights on developments in tuberculosis (TB) drug research.
Additionally, they will consult with each other on relevant regulatory, access, and clinical trial capacity strategies related to developing countries. These activities may open new avenues of possible common development in the future.
This collaboration agreement with the TB Alliance has been created to address the significant need to develop new TB drugs that will shorten treatment and be effective against drug-susceptible and drug-resistant strains of TB.
Jerome Premmereur, president and CEO of the TB Alliance, said: “This collaboration with Sanofi-Aventis underscores the commitment of the TB Alliance to partner with leaders in science and business to achieve our goal of making faster, better and affordable TB drug regimens available as soon as possible.”
Jean-Marc Herbert, senior vice president of discovery research at Sanofi-Aventis, said: “R&D at Sanofi-Aventis is firmly committed to the discovery of new medicines to combat TB. We are therefore delighted to have closer ties with the TB Alliance, which is recognized as a major driver in the discovery of new compounds in this field.”